NDC 68083-200 - Temsirolimus
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 68083-200
- Package NDCs from labels
- 68083-200-01
- Manufacturer
- Gland Pharma Limited
- Effective date
- 2022-10-07
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Temsirolimus Injection - Gland Pharma Limited | Gland Pharma Limited | 2022-10-07 | Human Prescription Drug Label |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 68083-200-01 | Temsirolimus | 1.0 mL in 1 VIAL, SINGLE-USE | INJECTION, SOLUTION, CONCENTRATE | 1.0 mL | 25 mg in 1mL | 6 |
DailyMed Dashboard NDC Coverage#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Anticoagulant Citrate Phosphate Dextrose (CPD) Blood-Pack Units in PL 146 Plastic | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE (CPD) | Fenwal, Inc. | 4a08a9ec-46a5-4fcf-80ee-5c33f1a8b746 | 2022-11-01 | XF417D3PSL | |
| Temsirolimus | TEMSIROLIMUS INJECTION | Gland Pharma Limited | d7ee3165-175d-4439-8740-fbfed18aaf0e | 2022-10-07 | Warnings, Adverse reactions | ANDA207383 68083-201-01 68083-202-01 68083-200-01 68083-202 722289 6dd61a73-2d62-4f94-9617-643d8b896fde d7ee3165-175d-4439-8740-fbfed18aaf0e |
| REFRESH OPTIVE Advanced | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN, POLYSORBATE 80 | Allergan, Inc. | ebd0839e-2e1d-4e0e-986c-19f1f5c76358 | 2022-09-15 | Warnings | 6OZP39ZG8H |
| REFRESH OPTIVE Advanced | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN, AND POLYSORBATE 80 | Allergan, Inc. | aaa943e4-7c38-4c5a-b7c0-5a656d8cafc0 | 2022-09-01 | Warnings | 6OZP39ZG8H |
| REFRESH Optive Mega-3 | CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN AND POLYSORBATE 80 | Allergan, Inc. | c5f2b3f2-2071-45bd-a010-67f848bc0233 | 2022-06-30 | Warnings | 6OZP39ZG8H |
| Ethylicum (ETOH, aka Alcoholus) | ETHYLICUM (ETOH, AKA ALCOHOLUS) | Hahnemann Laboratories, INC. | e1fef03a-ed76-4294-e053-2995a90aee67 | 2022-06-21 | 3K9958V90M | |
| ACD Blood-Pack Units (PL 146 PLASTIC) | ANTICOAGULANT CITRATE DEXTROSE (ACD) | Fenwal, Inc. | ba894daa-688e-4a9e-bd74-e71797f951bb | 2022-04-27 | XF417D3PSL | |
| ACD-A | ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A | Fenwal, Inc. | 22805f0d-ba58-41ea-b245-19980abcda22 | 2022-02-11 | XF417D3PSL | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | d763511e-f1a7-4014-94b9-f7ad8f023ff4 | 2021-12-02 | XF417D3PSL | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | cf9f43a0-c750-4cf0-ac49-176ab2105aab | 2021-12-02 | XF417D3PSL | |
| Hand Sanitizer | HAND SANITIZER | LS Promotions Inc. | a187d9fc-e5ce-2b48-e053-2995a90a0c0e | 2020-12-09 | Warnings | 3K9958V90M |
| Hand Sanitizer Lemon 2oz | ALCOHOL | Ningbo Rejoice International | b0a4159a-cb07-4ce6-e053-2995a90a76e7 | 2020-10-02 | Warnings | 3K9958V90M |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | ee831456-5962-4d5e-ad0c-69ab85860453 | 2020-06-03 | XF417D3PSL | |
| Temsirolimus | TEMSIROLIMUS | Fresenius Kabi USA, LLC | 1c207bed-10e3-46f0-ad2c-69d5e5c97736 | 2020-03-30 | Warnings, Adverse reactions | ANDA207383 722289 |
| Sanix Alcohol Hand Rub | ALCOHOL | Topiderm, Inc | a4fbb714-4f20-400a-ab98-f1c8807ce6fc | 2020-03-24 | Warnings | 3K9958V90M |
| Renacidin | CITRIC ACID, GLUCONOLACTONE AND MAGNESIUM CARBONATE | United-Guardian, Inc. | 13a9bbba-db21-4cba-991c-5d8afaf2ed74 | 2019-12-17 | Warnings, Adverse reactions | XF417D3PSL |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | e41adb4e-06fb-4141-ba55-50b043f3c9da | 2019-11-19 | XF417D3PSL | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 14445dfd-6041-40cd-a043-3f4da6bcb9c1 | 2019-11-18 | XF417D3PSL | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 2557199a-5f60-49d8-b093-1e0700211243 | 2019-11-18 | XF417D3PSL | |
| CPDA-1 | ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE | Fenwal, Inc. | 794f724c-87f0-49c1-9b26-c9e491978313 | 2019-11-18 | XF417D3PSL |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.